BXPHF (Botanix Pharmaceuticals) Tariff Resilience Score: 5/10 (As of Jul. 12, 2026)


What is Botanix Pharmaceuticals Tariff Resilience Score?

Botanix Pharmaceuticals BXPHF +14.04% Tariff Resilience Score is 5 as of Jul. 12, 2026. The stock has 7 warning signs investors should review. Among 1,370 Biotechnology companies, Botanix Pharmaceuticals ranks better than 62.41% on this metric.

Botanix Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Botanix Pharmaceuticals has BXPHF's pharmaceutical operations may face moderate tariff risks due to global supply chain dependencies for raw materials. However, its focus on innovative dermatology solutions and potential pricing power offer some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Botanix Pharmaceuticals might have Average Resilient.

Botanix Pharmaceuticals  (OTCPK:BXPHF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Botanix Pharmaceuticals Tariff Resilience Score Related Terms

BXPHF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Botanix Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Botanix Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 5 mean?
Botanix Pharmaceuticals (BXPHF) has a Tariff Resilience Score of 5 as of Jul. 12, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Botanix Pharmaceuticals ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Botanix Pharmaceuticals' Tariff Resilience Score too high?
Botanix Pharmaceuticals' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Botanix Pharmaceuticals' value of 5 is 25% above this industry median. Based on the distribution chart, Botanix Pharmaceuticals ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint.
How does Botanix Pharmaceuticals' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Botanix Pharmaceuticals ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Botanix Pharmaceuticals in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Botanix Pharmaceuticals' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Botanix Pharmaceuticals's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Botanix Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (BXPHF) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Botanix Pharmaceuticals (BXPHF), the current Tariff Resilience Score is 5 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Botanix Pharmaceuticals Business Description

Other Exchanges BOT:Australia
Address 41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.